Amgen announced that its investigational fusion protein, acquired through the Horizon Therapeutics deal, significantly eased the severity of Sjögren's disease in a phase 3 trial. The result is a bright spot for the company's pipeline, which has faced challenges in delivering wins since the acquisition.

The trial's success suggests the drug could become a new treatment option for Sjögren's, an autoimmune condition with limited therapies. However, the source does not provide specific efficacy data or safety details, so the magnitude of the benefit and potential risks remain unclear.

This is the only source available, so there are no conflicting reports. The outcome may help validate Amgen's $27.8 billion bet on Horizon, though broader commercial potential and regulatory hurdles are yet to be assessed.